Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

Ionis Pharmaceuticals' stock plunged 23% on July 9, 2026, after its Phase 3 CARDIO-TTRansform trial for eplontersen failed to meet its primary efficacy endpoint. The unexpected failure wiped out $3.3 billion in market capitalization. Hagens Berman has launched an investigation into whether the company was sufficiently transparent about the trial's data and design, potentially violating federal securities laws.

07/28/2026, 12:46 PM • GlobeNewswire

Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines Expand

The global oligonucleotide contract development and manufacturing organization (CDMO) market is experiencing strong growth driven by expanding RNA-targeted medicine pipelines, increased outsourcing of complex synthesis and manufacturing, and rising demand for precision medicine. The market is projected to grow at a 21.81% CAGR through 2031, with contract manufacturing leading at 51.68% market share in 2025. Antisense oligonucleotides dominate at 58.23% revenue, while siRNA is the fastest-growing segment at 23.25% CAGR. Asia-Pacific is the fastest-growing region at 24.56% CAGR, driven by capacity expansion in China, South Korea, and Japan.

07/15/2026, 4:10 AM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment

The global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.

05/18/2026, 2:33 PM • GlobeNewswire

Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight

The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are in mid and early stages. Recent developments include SanegeneBio's $110M Series B funding, FDA approvals for multiple orphan drug designations, and several companies advancing Phase II and Phase III trials.

05/14/2026, 1:00 PM • GlobeNewswire

Why Is Biogen Stock Falling Thursday?

Biogen stock fell 4.97% after reporting Phase 2 results for its Alzheimer's drug diranersen, which missed its primary endpoint but showed cognitive benefits and tau biomarker reductions across all doses. The company plans to advance the therapy to registrational development. Separately, Biogen completed its acquisition of Apellis Pharmaceuticals, adding two commercial drugs worth $689 million in 2025 revenue.

05/14/2026, 11:57 AM • Benzinga

GSK Targets China's Hepatitis B Market Through New Deal

GSK entered an exclusive strategic collaboration with Sino Biopharmaceutical to accelerate bepirovirsen, an investigational hepatitis B treatment, in mainland China. The drug is under priority regulatory review in China and showed positive Phase 3 trial data. GSK will retain marketing authorization and regulatory responsibility while CTTQ handles distribution and promotional activities. Additionally, GSK announced the final tranche of its £2 billion share repurchase program.

05/11/2026, 12:03 PM • Benzinga

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight

The complement inhibitors market is projected to experience strong growth through 2036, driven by rising prevalence of complement-mediated diseases, increased R&D efforts, and approval of new therapeutic agents. The US represents the largest market, with IgAN showing approximately 135,000 diagnosed prevalent cases. Key emerging therapies from major pharmaceutical companies are expected to expand treatment options across multiple indications including PNH, aHUS, CIDP, and IgAN.

04/30/2026, 1:00 PM • GlobeNewswire

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

04/29/2026, 1:00 PM • GlobeNewswire

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.

04/22/2026, 1:00 PM • GlobeNewswire

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Praxis Precision Medicines announced positive Phase 1/2 trial results for elsunersen (PRAX-222), an antisense oligonucleotide treatment for SCN2A developmental and epileptic encephalopathy. The drug demonstrated a 77% placebo-adjusted seizure reduction, with 71% of treated patients achieving >50% seizure reduction. All elsunersen-treated patients showed improvements in sleep, motor function, and attention, with no serious adverse events reported.

04/06/2026, 8:00 AM • GlobeNewswire

Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market

Ionis Pharmaceuticals announced a significant price reduction for its triglyceride-lowering drug Tryngolza (olezarsen) from $595,000 to $40,000 annually, effective April 1. The repricing positions the therapy competitively ahead of an expected FDA decision on label expansion into severe hypertriglyceridemia (sHTG) by June 30. Analysts view the move positively as it aligns with payer contracting cycles and could drive substantial revenue upside, with peak sales projections potentially exceeding $2 billion.

03/26/2026, 1:47 PM • Benzinga

When Insider Selling Is a Good Thing: 2 Stocks to Watch

The article examines two stocks experiencing insider selling but maintaining bullish long-term outlooks. Waste Management insiders sold ~$25M after hitting all-time highs, but institutional accumulation and growing dividends support the outlook. Ionis Pharmaceuticals faces heavier insider and institutional selling, though analysts see 25% upside driven by Olezarsen's commercial ramp. Both stocks have pulled back from early 2026 highs, creating potential entry points.

03/24/2026, 3:07 PM • Investing

When Insider Selling Is a Good Thing: 2 Stocks to Watch

The article examines insider selling at Waste Management and Ionis Pharmaceuticals, arguing that profit-taking by insiders at these stocks presents buying opportunities. Waste Management benefits from institutional accumulation, strong dividend growth prospects, and analyst support despite insider sales. Ionis Pharmaceuticals faces heavier selling pressure but analysts project 25% upside driven by commercial growth of its drug Olezarsen and a bullish long-term earnings outlook.

03/24/2026, 10:24 AM • Investing

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

03/20/2026, 12:07 PM • The Motley Fool